Wall Street analysts forecast that ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) will report earnings of $0.99 per share for the current quarter, Zacks reports. Two analysts have made estimates for ANI Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at $0.98 and the highest estimate coming in at $1.00. ANI Pharmaceuticals posted earnings per share of $1.09 in the same quarter last year, which would indicate a negative year over year growth rate of 9.2%. The company is scheduled to report its next quarterly earnings report on Thursday, November 2nd.

According to Zacks, analysts expect that ANI Pharmaceuticals will report full-year earnings of $3.87 per share for the current financial year, with EPS estimates ranging from $3.86 to $3.88. For the next financial year, analysts forecast that the company will report earnings of $4.56 per share, with EPS estimates ranging from $4.40 to $4.71. Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that cover ANI Pharmaceuticals.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported $0.98 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.79 by $0.19. ANI Pharmaceuticals had a return on equity of 22.70% and a net margin of 3.35%. The firm had revenue of $44.80 million during the quarter, compared to analysts’ expectations of $43.20 million. During the same period in the previous year, the firm earned $1.11 earnings per share. The company’s revenue was up 43.0% on a year-over-year basis.

Several brokerages have recently commented on ANIP. BidaskClub upgraded ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, August 18th. Canaccord Genuity restated a “buy” rating and issued a $60.00 target price on shares of ANI Pharmaceuticals in a research note on Wednesday, August 9th. Zacks Investment Research upgraded ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, July 5th. Guggenheim restated a “buy” rating and issued a $80.00 target price on shares of ANI Pharmaceuticals in a research note on Tuesday, July 4th. Finally, ValuEngine downgraded ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $65.33.

ILLEGAL ACTIVITY WARNING: “Analysts Anticipate ANI Pharmaceuticals, Inc. (ANIP) to Announce $0.99 EPS” was published by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this news story can be accessed at https://www.americanbankingnews.com/2017/09/15/analysts-anticipate-ani-pharmaceuticals-inc-anip-to-announce-0-99-eps.html.

A number of hedge funds have recently added to or reduced their stakes in the business. Mesirow Financial Investment Management Inc. acquired a new position in ANI Pharmaceuticals during the 2nd quarter valued at about $506,000. Dynamic Technology Lab Private Ltd acquired a new position in ANI Pharmaceuticals during the 2nd quarter valued at about $210,000. Raymond James Financial Services Advisors Inc. boosted its stake in ANI Pharmaceuticals by 67.8% during the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 9,493 shares of the specialty pharmaceutical company’s stock valued at $444,000 after purchasing an additional 3,837 shares during the last quarter. Dana Investment Advisors Inc. boosted its stake in ANI Pharmaceuticals by 0.8% during the 2nd quarter. Dana Investment Advisors Inc. now owns 42,720 shares of the specialty pharmaceutical company’s stock valued at $1,999,000 after purchasing an additional 341 shares during the last quarter. Finally, Western Standard LLC acquired a new position in ANI Pharmaceuticals during the 2nd quarter valued at about $693,000. Institutional investors and hedge funds own 55.86% of the company’s stock.

ANI Pharmaceuticals (ANIP) traded down 0.170% on Friday, reaching $49.975. The company’s stock had a trading volume of 40,621 shares. ANI Pharmaceuticals has a 52-week low of $42.23 and a 52-week high of $69.85. The stock has a market cap of $581.61 million, a price-to-earnings ratio of 109.354 and a beta of 3.10. The firm’s 50-day moving average price is $46.66 and its 200-day moving average price is $48.01.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.

Get a free copy of the Zacks research report on ANI Pharmaceuticals (ANIP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ANI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.